SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton LJ 3rd, O'Fallon WM, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001; 76: 5939.
  • 2
    Van Vollenhoven RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2002; 3: 2331.
  • 3
    Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 29247.
  • 4
    Valtysdottir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren's syndrome as an isolated sign of impaired HPA axis function. J Rheumatol 2001; 28: 125965.
  • 5
    Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjogren's syndrome: proposed criteria for classification. Arthritis Rheum 1986; 29: 57785.
  • 6
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 7
    Pillemer S, Gulko P, Ligier S, Yarboro C, Gourley M, Goldbach-Mansky R, et al. Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. J Rheumatol 2003; 30: 413.
  • 8
    van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25: 2859.
  • 9
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 10
    Ben-Nathan D, Padgett DA, Loria RM. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J Med Microbiol 1999; 48: 42531.
  • 11
    Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2000; 26: 88195.
  • 12
    Barry NN, McGuire JL, van Vollenhoven RF. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response. J Rheumatol 1998; 25: 23526.
  • 13
    Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002; 46: 18209.
  • 14
    Brennan MT, Sankar V, Leakan RA, Grisius MM, Collins MT, Fox PC, et al. Sex steroid hormones in primary Sjogren's syndrome. J Rheumatol 2003; 30: 126771.
  • 15
    Drosos AA, van Vliet-Dascalopoulou E, Andonopoulos AP, Galanopoulou V, Skopouli FN, Moutsopoulos HM. Nandrolone decanoate (deca-durabolin) in primary Sjogren's syndrome: a double blind pilot study. Clin Exp Rheumatol 1988; 6: 537.